Clinical Trials Logo
  1. Home
  2. Myeloid Leukemia
  3. NCT00126893

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Myeloid Leukemia Clinical Trial

Official title:
Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Clinical Trial Summary

This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00126893
Study type Interventional
Source Celgene
Contact
Status Terminated
Phase Phase 1
Start date October 2005
Completion date September 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Terminated NCT00543972 - Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia Phase 1
Completed NCT00521664 - A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups Phase 3
Completed NCT05363488 - Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Completed NCT01380756 - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia Phase 1
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Completed NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Phase 2
Active, not recruiting NCT04714372 - FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Phase 1
Recruiting NCT06235801 - A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT02763475 - NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents Phase 2
Terminated NCT01643603 - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Phase 1
Completed NCT00497991 - Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia Phase 1
Withdrawn NCT05309018 - Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
Not yet recruiting NCT05787951 - Frequency and Risk Factors of Acute Myeloid Leukemia
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT02719821 - Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation N/A
Active, not recruiting NCT00111345 - Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Phase 2/Phase 3
Completed NCT00114764 - Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) Phase 2
Recruiting NCT05871008 - Integrated Actionable Aging Assessment for Cancer Patients Pilot N/A
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2